Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magnevist-enhanced MRA in Peripheral Vascular Disease
NCT00185276Phase 3Completed
- Sponsor
- Bayer
- Start
- Mar 2003
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of gadopentetate dimeglumine in peripheral vascular disease (PVD), sponsored by Bayer. Started Mar 2003; status: completed.
02
Drugs
gadopentetate dimeglumine
03
Conditions
peripheral vascular disease (PVD)
Beyond the preview
Go deeper on NCT00185276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00185276.